NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

NCT03476655

CompletedN/A

Sponsor: Johnson & Johnson Private Limited

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Interventions: Ibrutinib

Countries: India

The purpose of this study is to describe the effectiveness (overall response rate \[ORR\] and time to progression \[TPP\]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
* CLL or MCL participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 mg) based on independent clinical judgment of treating physicians

Exclusion Criteria:

\- Any contraindications to ibrutinib use according to the current version of the Prescribing information in India

Locations (8)

Ahmedabad, India
Bangalore, India
Gurgaon, India
Hyderabad, India
Jaipur, India
Kolkata, India
New Delhi, India
Pune, India